abstract |
the present invention relates, among other things, to stable formulations comprising an oncostatin m (osmr) antireceptor antibody and having a ph ranging from approximately 6.0? 7.6, where less than approximately 5% of the anti-osmr antibody exists as a high molecular weight (hmw) species in the formulation. |